DE69526240D1 - Verbindungen und verfahren zur verminderung der bildung von beta-proteinfilamenten und neurotoxizität - Google Patents
Verbindungen und verfahren zur verminderung der bildung von beta-proteinfilamenten und neurotoxizitätInfo
- Publication number
- DE69526240D1 DE69526240D1 DE69526240T DE69526240T DE69526240D1 DE 69526240 D1 DE69526240 D1 DE 69526240D1 DE 69526240 T DE69526240 T DE 69526240T DE 69526240 T DE69526240 T DE 69526240T DE 69526240 D1 DE69526240 D1 DE 69526240D1
- Authority
- DE
- Germany
- Prior art keywords
- neurotoxicity
- connections
- methods
- film formation
- beta protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
- G01N2333/8125—Alpha-1-antitrypsin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32849194A | 1994-10-25 | 1994-10-25 | |
US08/417,937 US5780587A (en) | 1990-08-24 | 1995-04-06 | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
PCT/US1995/013681 WO1996012736A2 (en) | 1994-10-25 | 1995-10-25 | COMPOUNDS AND METHODS FOR INHIBITING β-PROTEIN FILAMENT FORMATION AND NEUROTOXICITY |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69526240D1 true DE69526240D1 (de) | 2002-05-08 |
DE69526240T2 DE69526240T2 (de) | 2002-11-21 |
Family
ID=26986406
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535462T Expired - Lifetime DE69535462T2 (de) | 1994-10-25 | 1995-10-25 | Zusammensetzung und Verfahren zur Inhibition der Filamentbildung des Amyloid-Betaproteins und seiner Neutotoxizität |
DE69526240T Expired - Lifetime DE69526240T2 (de) | 1994-10-25 | 1995-10-25 | Verbindungen und verfahren zur verminderung der bildung von beta-proteinfilamenten und neurotoxizität |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535462T Expired - Lifetime DE69535462T2 (de) | 1994-10-25 | 1995-10-25 | Zusammensetzung und Verfahren zur Inhibition der Filamentbildung des Amyloid-Betaproteins und seiner Neutotoxizität |
Country Status (5)
Country | Link |
---|---|
US (2) | US5780587A (de) |
EP (2) | EP0787146B1 (de) |
CA (1) | CA2203825A1 (de) |
DE (2) | DE69535462T2 (de) |
WO (1) | WO1996012736A2 (de) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0632008T3 (da) * | 1993-06-01 | 1998-09-23 | Ono Pharmaceutical Co | Pentansyrederivater |
AU1072897A (en) * | 1995-12-12 | 1997-07-03 | Karolinska Innovations Ab | Peptide binding the klvff-sequence of amyloid beta |
US6071493A (en) * | 1996-09-20 | 2000-06-06 | Baylor College Of Medicine | Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation |
US6043283A (en) * | 1996-09-20 | 2000-03-28 | Baylor College Of Medicine | Tyramine compounds and their neuronal effects |
US20050282198A1 (en) * | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
GB9711040D0 (en) * | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
NO314086B1 (no) * | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
MXPA01004317A (es) * | 1998-10-30 | 2003-06-06 | Jordan L Holtzman | Un complejo de una chaperona con -amiloideo y metodos que emplean este complejo. |
DE19855469C2 (de) * | 1998-12-01 | 2001-01-11 | Michael Esrich | Verfahren zur Bestimmung des Apolipoprotein-E-Genotyps in einer menschlichen Probe |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US20040146521A1 (en) * | 1999-06-01 | 2004-07-29 | Schenk Dale B. | Prevention and treatment of synucleinopathic disease |
US6689753B1 (en) * | 1999-11-05 | 2004-02-10 | Axonyx, Inc. | β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide |
US20070135337A2 (en) * | 1999-11-29 | 2007-06-14 | Neurochem (International) Limited | Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases |
US20020094335A1 (en) * | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
AU2001229592A1 (en) * | 2000-01-21 | 2001-07-31 | University Of Connecticut Health Center | Vaccines against neurodegenerative disorders |
AU783144B2 (en) * | 2000-02-21 | 2005-09-29 | H. Lundbeck A/S | Novel method for down-regulation of amyloid |
BR0108566A (pt) * | 2000-02-21 | 2002-11-19 | Pharmexa As | Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
DE10121255A1 (de) * | 2001-04-30 | 2002-11-07 | Switch Biotech Ag | Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen |
AU2002254999B2 (en) * | 2001-04-30 | 2007-07-26 | Bayer Innovation Gmbh | Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
US20080311581A1 (en) * | 2001-11-19 | 2008-12-18 | David Wyllie | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
US20030171556A1 (en) * | 2001-12-13 | 2003-09-11 | Chi-Bom Chae | Beta-amyloid binding factors and inhibitors thereof |
US7795213B2 (en) * | 2001-12-13 | 2010-09-14 | Posco | Methods of contacting β amyloid protein with VEGF |
US20060057107A1 (en) * | 2001-12-21 | 2006-03-16 | Shaked Ze Ev | Combination treatment for multiple sclerosis |
EP1820806A1 (de) * | 2006-02-16 | 2007-08-22 | Crossbeta Biosciences B.V. | Affinitätsbereiche |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1380290A1 (de) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-Beta-Strukturweg und seine therapeutische Relevanz |
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
AU2003256610A1 (en) * | 2002-08-16 | 2004-03-03 | Pharmacia & Upjohn Company Llc | ISOFORM SPECIFIC INTERACTIONS OF APOLIPOPROTEIN E TO AN INTERMEDIATE CONFORMATION OF ALZHEIMER ABeta PEPTIDE |
US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US20050265983A1 (en) * | 2002-11-17 | 2005-12-01 | Eldad Melamed | Methods, nucleic acid constructs and cells for treating neurodegenerative disorders |
AU2004209981B2 (en) * | 2003-02-01 | 2009-02-26 | Janssen Sciences Ireland Uc | Active immunization to generate antibodies to soluble A-beta |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
WO2006066049A2 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
ES2524996T3 (es) | 2005-06-16 | 2014-12-16 | Ramot At Tel Aviv University Ltd. | Células aisladas y poblaciones que comprenden a las mismas para el tratamiento de enfermedades del SNC |
US20080118529A1 (en) * | 2005-07-13 | 2008-05-22 | Gebbink Martijn Frans Ben Gera | Adjuvation Through Cross -Beta Structure |
US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
EP1910844B1 (de) * | 2005-07-13 | 2012-04-18 | Crossbeta Biosciences B.V. | Cross-beta-struktur-bindende verbindungen |
US20070015133A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein |
EP1951750A4 (de) * | 2005-11-10 | 2009-12-09 | Roskamp Res Llc | Modulation der angiogenese durch a-beta-peptidfragmente |
WO2007066338A1 (en) * | 2005-12-08 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Isolated oligodendrocyte-like cells and populations comprising same for the treatment of cns diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
JP5558834B2 (ja) * | 2007-02-23 | 2014-07-23 | ヤンセン アルツハイマー イミュノセラピー | シヌクレイノパチーおよびアミロイド形成疾患(amyloidogenicdisease)の予防および処置 |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
DK2182983T3 (da) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer |
US8932558B2 (en) * | 2007-10-05 | 2015-01-13 | Plaxgen Inc | Multi-subunit biological complexes for treatment of plaque-associated diseases |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2058000A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung |
EP2058001A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Steigerung der Immunogenizität von Antigenen |
US8663987B2 (en) | 2008-05-28 | 2014-03-04 | Ramot At Tel-Aviv University Ltd. | Mesenchymal stem cells for the treatment of CNS diseases |
AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2018081250A1 (en) * | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Neuronal and oligodendrocyte survival modulation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4303592A (en) * | 1980-01-09 | 1981-12-01 | Center For Blood Research, Inc. | Amidinophenylmethylsulfonylfluoride |
JPS56128774A (en) * | 1980-03-14 | 1981-10-08 | Microbial Chem Res Found | New physiologically active substance ebelactone and its preparation |
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
IE910713A1 (en) | 1990-03-05 | 1991-09-11 | Cephalon Inc | Chymotrypsin-like proteases |
HUT69771A (en) * | 1990-08-17 | 1995-09-28 | Univ Boston | Proteases causing abnormal degradation of amyloid beta-proteine precursors |
WO1992003474A1 (en) * | 1990-08-24 | 1992-03-05 | President And Fellows Of Harvard College | METHOD OF INTERFERING WITH FORMATION OF α-ANTICHYMOTRYPSIN-β-PROTEIN COMPLEX AND SYNTHETIC PEPTIDES FOR USE THEREIN |
US5338663A (en) * | 1990-08-24 | 1994-08-16 | President And Fellows Of Harvard College | Method of identifying inhibitors of β-protein esterase activity |
US5604102A (en) * | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
WO1994009364A1 (en) * | 1992-10-13 | 1994-04-28 | Duke University | Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein |
JPH11514333A (ja) * | 1995-03-14 | 1999-12-07 | プレーシス ファーマスーティカルズ インコーポレイテッド | アミロイドの凝集の調節剤 |
-
1995
- 1995-04-06 US US08/417,937 patent/US5780587A/en not_active Expired - Lifetime
- 1995-10-25 EP EP95937610A patent/EP0787146B1/de not_active Expired - Lifetime
- 1995-10-25 WO PCT/US1995/013681 patent/WO1996012736A2/en active IP Right Grant
- 1995-10-25 DE DE69535462T patent/DE69535462T2/de not_active Expired - Lifetime
- 1995-10-25 DE DE69526240T patent/DE69526240T2/de not_active Expired - Lifetime
- 1995-10-25 EP EP01202212A patent/EP1172377B1/de not_active Revoked
- 1995-10-25 CA CA002203825A patent/CA2203825A1/en not_active Abandoned
-
1997
- 1997-08-19 US US08/914,694 patent/US6214569B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2203825A1 (en) | 1996-05-02 |
DE69535462T2 (de) | 2008-01-03 |
DE69526240T2 (de) | 2002-11-21 |
WO1996012736A3 (en) | 1996-08-01 |
US5780587A (en) | 1998-07-14 |
US6214569B1 (en) | 2001-04-10 |
EP0787146B1 (de) | 2002-04-03 |
WO1996012736A2 (en) | 1996-05-02 |
EP1172377A1 (de) | 2002-01-16 |
EP0787146A1 (de) | 1997-08-06 |
DE69535462D1 (de) | 2007-05-24 |
EP1172377B1 (de) | 2007-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69526240T2 (de) | Verbindungen und verfahren zur verminderung der bildung von beta-proteinfilamenten und neurotoxizität | |
DE69424744T2 (de) | Verfahren und System zur Verwaltung von Komponentenverbindungen | |
DE69316810T2 (de) | SiGe-SOI-MOSFET und Verfahren zur Herstellung | |
DE69405408D1 (de) | Objektorientiertes system und verfahren zur hardwarekonfiguration | |
DE69534700D1 (de) | Halbleiteranordnungen und verfahren | |
DE69519235D1 (de) | Hämorrhoidenzusammensetzungen und verfahren zur verwendung | |
DE69521549D1 (de) | Verfahren zur Verwaltung gemeinsamer Mittel mehrerer Verarbeitungseinheiten | |
ATE351910T1 (de) | Ob-fusionsprotein enthaltende zusammensetzungen und verfahren | |
DE69526322T2 (de) | System und Verfahren zur Indexierung von Multimedia-Programmen | |
DE69502526D1 (de) | Verfahren und Vorrichtung zur Kontrolle der Verbreitung von digitaler Information | |
DE69331024T2 (de) | Verfahren und Vorrichtungen zur Bildung von Protokollen | |
DE69427826T2 (de) | Verfahren und system zur reinigung von bohrlöchern | |
ATA124894A (de) | Verfahren zur direktreduktion von eisenoxidhältigem material | |
DE59703443D1 (de) | Verfahren zur herstellung von aminen und aminonitrilen | |
DE69728802D1 (de) | Wirkstoffimmobilisierte Partikel und Verfahren zur Reinigung von Proteinen | |
DE69834613D1 (de) | Halbleiterbauelement und verfahren zur dessen herstellung | |
DE69602355T2 (de) | Verfahren und zusammensetzung zur reinigung von oberflächen | |
DE69523550T2 (de) | Einrichtung und Verfahren zur Quantisierung | |
DE69128406D1 (de) | Lateraler MOSFET und Verfahren zur Herstellung | |
DE69529888T2 (de) | Einrichtung und Verfahren zur Quantisierung | |
DE59507436D1 (de) | Verfahren zur direktreduktion von eisenoxidhältigem material | |
DE69526841T2 (de) | Verfahren zur Wiedergabe | |
DE69503347T2 (de) | System und Verfahren zur Befestigung von Leitungen | |
DE69523170D1 (de) | Verfahren zur isolierung von molkenproteine | |
DE69534231D1 (de) | Verfahren und Einrichtung zur Verwaltung von Mehrfachverbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
R082 | Change of representative |
Ref document number: 787146 Country of ref document: EP Representative=s name: PATENTANWAELTE WALLACH, KOCH & PARTNER, DE |